報價延遲最少15分鐘:2025/03/28 06:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.57 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.93/-0.53
|
|
企業價值
306.38M
|
| 資產負債 |
|
每股賬面淨值
0.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
308.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 06:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. |